At the onset of the SARS-CoV-2 pandemic, it was questioned whether neurological syndromes (NS) could emerge with the new virus. Medical literature supported this by replicating occurrences from past viral outbreaks, suggesting increased morbidity and mortality risks. We assembled the NeurocovBR study group, comprising four neurological reference centers and a robust virology laboratory. Sites were located in two COVID-19 hotspot states. Here, we present the clinical and epidemiological characteristics of this cohort.
Our study supports the link between neurological syndromes and COVID-19. Incidence correlated with SARS-CoV-2 infection waves, and neuro-COVID patients had worse outcomes than other COVID-19 patients. Vascular syndromes were the most common and were more severe than those seen before the pandemic.